DexTech Medical operates in biotechnology. The company conducts research and development in the field of urological oncology, where common diseases include prostate cancer. A large part of the research is carried out in collaboration with other international players, research institutes and universities. The largest operations are found in the Nordic market. The company was founded in 2004 and is headquartered in Uppsala.
CEO
Chairperson of the Board
Board
| Name | Capital % | Votes % | Date |
|---|---|---|---|
| Svante Wadman | 21,45 | 21,45 | 2025-12-23 |
| Anders Holmberg | 8,51 | 8,51 | 2025-12-23 |
| Sten Nilsson | 7,75 | 7,75 | 2025-12-23 |
| Donald Ericsson Fastigheter VI AB | 6,08 | 6,08 | 2025-12-23 |
| Gösta Lundgren | 5,96 | 5,96 | 2025-12-23 |
| Hans Andersson med familj | 5,68 | 5,68 | 2025-06-30 |
| Avanza Pension | 4,42 | 4,42 | 2025-12-23 |
| Nordnet Pensionsförsäkring | 3,59 | 3,59 | 2025-12-23 |
| Mats Ragnarsson Holmberg | 2,16 | 2,16 | 2025-12-23 |
| Peter Kanekrans | 2,07 | 2,07 | 2025-12-23 |
2026-05-05 Interim Report 2026-Q3
2026-08-31 Year End Report 2026
